Overview

Cenobamate Open-Label Extension Study for YKP3089C025

Status:
Enrolling by invitation
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025
Phase:
Phase 3
Details
Lead Sponsor:
SK Life Science, Inc.
Treatments:
Cenobamate